利伐沙班用于减重手术后静脉血栓预防的疗效与安全性:一项随机临床试验
这项评估者盲法、2期、多中心随机临床试验于2018年7月1日至2021年6月30日在瑞士3家学术与非学术医院开展,将272例减重手术后患者随机分为口服利伐沙班10 mg/d 7天(短期预防)或28天(长期预防)两组。主要疗效终点为术后28天内深静脉血栓(症状性或无症状性)与肺栓塞的复合终点,仅1例(0.4%)发生无症状血栓(袖状胃切除、长期预防组)。大出血或临床相关非大出血共5例(1.9%),短期组2例、长期组3例;临床无显著意义出血10例(3.7%),短期组3例、长期组7例。作者认为减重术后早期每日一次10 mg利伐沙班在短期和长期预防组均有效且安全。
要点
- 减重术后口服利伐沙班10 mg/d:7天与28天方案术后28天内血栓复合终点仅1例(0.4%),为袖状胃切除后长期预防组的无症状血栓。
- 大出血或临床相关非大出血共5例(1.9%):短期预防组2例 vs 长期预防组3例。
- 临床无显著意义出血共10例(3.7%):短期预防组3例 vs 长期预防组7例。
- 该研究为2期、评估者盲法、多中心随机临床试验,共272例随机(7天组134例、28天组135例),来自瑞士3家医院。
- 作者结论:减重术后早期每日一次10 mg利伐沙班在短期和长期预防组均有效且安全。
适用人群与场景
- 减重手术后患者:272例随机,平均(SD)年龄40.0(12.1)岁,女性216例(80.3%),平均体重指数42.2。
- 来自瑞士3家学术与非学术医院,2018年7月1日至2021年6月30日纳入。
处置流程与药物剂量
- 减重手术后第1天随机,口服利伐沙班10 mg/d,分为7天(短期预防)或28天(长期预防)。
- 7天组134例接受7天静脉血栓栓塞预防疗程,28天组135例接受28天疗程。
研究设计与关键结果
- 设计:评估者盲法、2期、多中心随机临床试验;2018年7月1日至2021年6月30日;瑞士3家学术与非学术医院;272例随机(7天组134例、28天组135例)。
- 主要疗效终点为术后28天内深静脉血栓(症状性或无症状性)与肺栓塞的复合终点:仅1例血栓栓塞事件(0.4%),为袖状胃切除后接受长期预防患者发生的无症状血栓。
- 大出血或临床相关非大出血共5例(1.9%):短期预防组2例 vs 长期预防组3例。
- 临床无显著意义出血共10例(3.7%):短期预防组3例 vs 长期预防组7例。
- 死亡率:主要安全结局包括死亡率;原文未报告具体死亡例数。
- 作者结论:减重术后早期每日一次10 mg利伐沙班在短期和长期预防组均有效且安全。
证据类型、等级与局限
- 证据类型:评估者盲法、2期、多中心随机临床试验(ClinicalTrials.gov NCT03522259)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为减重术后早期每日一次10 mg利伐沙班预防静脉血栓栓塞在短期(7天)和长期(28天)方案均有效且安全。
- 适用人群为减重手术后患者;不适用人群原文未报告。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality after bariatric surgery. Clinical end point studies on thromboprophylaxis with direct oral anticoagulants in patients undergoing bariatric surgery are lacking.
OBJECTIVE: To assess the efficacy and safety of a prophylactic dose of 10 mg/d of rivaroxaban for both 7 and 28 days after bariatric surgery.
DESIGN, SETTING, AND PARTICIPANTS: This assessor-blinded, phase 2, multicenter randomized clinical trial was conducted from July 1, 2018, through June 30, 2021, with participants from 3 academic and nonacademic hospitals in Switzerland.
INTERVENTION: Patients were randomized 1 day after bariatric surgery to 10 mg of oral rivaroxaban for either 7 days (short prophylaxis) or 28 days (long prophylaxis).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the composite of deep vein thrombosis (symptomatic or asymptomatic) and pulmonary embolism within 28 days after bariatric surgery. Main safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and mortality.
RESULTS: Of 300 patients, 272 (mean [SD] age, 40.0 [12.1] years; 216 women [80.3%]; mean body mass index, 42.2) were randomized; 134 received a 7-day and 135 a 28-day VTE prophylaxis course with rivaroxaban. Only 1 thromboembolic event (0.4%) occurred (asymptomatic thrombosis in a patient undergoing sleeve gastrectomy with extended prophylaxis). Major or clinically relevant nonmajor bleeding events were observed in 5 patients (1.9%): 2 in the short prophylaxis group and 3 in the long prophylaxis group. Clinically nonsignificant bleeding events were observed in 10 patients (3.7%): 3 in the short prophylaxis arm and 7 in the long prophylaxis arm.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, once-daily VTE prophylaxis with 10 mg of rivaroxaban was effective and safe in the early postoperative phase after bariatric surgery in both the short and long prophylaxis groups.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03522259.
参考来源
- Kröll D, Nett PC, Rommers N, et al. Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37227726. doi:10.1001/jamanetworkopen.2023.15241
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。